Wird geladen...
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. OBJECTIVES: 1. Discuss the mode of acti...
Gespeichert in:
| Veröffentlicht in: | Curr Cancer Drug Targets |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Bentham Science Publishers
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652078/ https://ncbi.nlm.nih.gov/pubmed/28359238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1568009617666170330120452 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|